Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Cash & Equivalents (2016 - 2025)

INVO Fertility (IVF) has disclosed Cash & Equivalents for 15 consecutive years, with $355891.0 as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents fell 28.82% to $355891.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $355891.0 through Sep 2025, down 28.82% year-over-year, with the annual reading at $741396.0 for FY2024, 218.98% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $355891.0 at INVO Fertility, down from $500000.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $8.4 million in Q1 2021, with the low at $90135.0 in Q4 2022.
  • Average Cash & Equivalents over 5 years is $2.1 million, with a median of $840407.0 recorded in 2025.
  • The sharpest move saw Cash & Equivalents surged 2306.64% in 2021, then tumbled 98.41% in 2022.
  • Over 5 years, Cash & Equivalents stood at $5.7 million in 2021, then crashed by 98.41% to $90135.0 in 2022, then surged by 157.86% to $232424.0 in 2023, then surged by 218.98% to $741396.0 in 2024, then plummeted by 52.0% to $355891.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $355891.0, $500000.0, and $840407.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.